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ABSTRACT 
CHAU T. TRUONG: Development and Evaluation of Quercetin Nanoparticles 
and Hot Melt Cast Films for Retinal Neuroprotection 
(Under the direction of Soumyajit Majumdar) 
 
Purpose: 
The aim of this study was to prepare optimized nanoparticles and hot melt cast films of 
quercetin and to investigate the release and permeability profile across corneal 
membranes. 
Method: 
Quercetin dissolved in DMSO was mixed with glycerin and added to the lipid phase of 
either Glycerol monostearate or Miglyol 812
®
 combined with Compritol ATO 888
®
. The 
aqueous phase of Tween 80
®
, Poloxomer 188
®
, and water was added, and the premix was 
homogenized, probe sonicated, and cooled to form the nanoparticles. Quercetin and 
polyethylene oxide N10 were mixed, and the blend was pressed and melted to prepare the 
films. Physicochemical profiles for nanoparticles were analyzed, and permeability across 
rabbit cornea was studied for both formulations using side by side diffusion apparatuses. 
Results: 
The SLNs and NLCs demonstrated particle sizes of 65.4 and 46.1 r.mn, polydispersity 
indices of 0.29 and 0.18, zeta potentials of -12.3 and -16.2 mV, assay of 78.4 and 86.6, 
and entrapment efficiencies of 90.9and 93.4, respectively. Transcorneal flux of quercetin 
nanoparticles, film and control were 0.036, 0.144, and 0.026, respectively.  
Conclusion: 
These results demonstrate that all formulations can be successfully employed for delivery 
of quercetin into the eye through the topical route of administration, with films showing 
significantly better transcorneal permeability. 
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1. INTRODUCTION: 
 With increased age comes declining health conditions and increased 
prevalence in diseases. Included in this broad category is the deterioration of vision due 
to a variety of factors contributing to a number of ophthalmic diseases. These diseases 
can include age-related macular degeneration, cataracts, diabetic retinopathy, and 
glaucoma. According to statistics by the National Eye Institute, several millions of people 
above the age of forty are affected by one of these conditions. From the total population 
of those above age forty in the 2010 U.S. Census (n = 142,648,393), 36,883,997 adults 
suffered from vision impairment due to all of the ophthalmic diseases listed above 
combined (NEI “Prevalence”, 2016). This is approximately over a quarter (25.9%) of 
adults over age forty who are affected with vision impairment. As age increases, the 
prevalence rates of all vision impairment also increase, rising significantly around ages 
75-79 in all ethnicities, as shown in Figure 1. 
 
 
 
 
 
Figure 1. 2010 U.S. Prevalence Rates: All Vision Impairment 
Source: National Eye Institute. All Vision Impairment. Available at: 
https://nei.nih.gov/eyedata/vision_impaired#1. Accessed March 27, 2017. 
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Over the course of ten years, starting from the year 2000, the prevalence of vision 
impairment has increased by almost 130% (NEI “Vision”, 2016). These trends are 
expected to continue with each subsequent year so that by the year 2030, there will be 
almost a two-fold increase in prevalence of vision impairment compared to that in 2010, 
and by 2050, there will be more than a 3-fold increase in prevalence, as shown in Table 1 
and Figure 2. 
Table 1. Table Projections for Vision Impairment (2010-2030-2050) 
 
Year All White  Black Hispanic Other 
2010 4,195,966 3,398,977 330,644 290,781 175,564 
2030 7,169,680 5,277,689 618,110 840,497 433,383 
2050 13,026,870 9,019,189 1,047,986 2,000,853 958,842 
Total 
Population 
142,648,393 103,846,437 15,190,777 14,901,369 8,709,810 
Source: National Eye Institute. Vision Impairment Tables. Available at: 
https://nei.nih.gov/ eyedata/vision_impaired/tables. Accessed March 27, 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Chart Projections for Vision Impairment (2010-2030-2050) 
Source: National Eye Institute. All Vision Impairment. Available at: 
https://nei.nih.gov/eyedata/vision_impaired#1. Accessed March 27, 2017. 
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 One cause of vision impairment is due to uncontrolled exposure to 
reactive oxidative species, or ROS. These are species that are produced naturally in the 
body as a byproduct of adenosine triphosphate, or ATP, production, the energy source 
that is used for every day function and processes (Prunty, 2015). They are free radicals 
that contain oxygen and are the most common type produced in tissues (NCI, 2014). 
They can affect cells by damaging important cellular components, such as DNA, 
proteins, and membranes. The mitochondria, an efficient organelle found abundantly in 
the body’s cells and tissues, produce the largest quantities of ROS as it is the largest 
contributor to ATP synthesis (90% of the body’s energy) [UMDF, 2017]. The body has 
natural antioxidant mechanisms to protect against ROS, but when ROS are overproduced, 
these mechanisms are overwhelmed (Prunty, 2015). This leads to oxidative stress 
cascades on cells and tissues, which causes them to become damaged and eventually die 
off. In the eye, ROS damage the cells of the retina, which plays an important role in 
converting visual images into electrical impulses for the brain to interpret. As the 
photoreceptor cells of the retina die off, vision worsens as the eye has less capability to 
convert those images to impulses. The longer the period of exposure to ROS, the more 
damage is done to the retina. Prolonged damage to the retina exacerbates retinal 
degradation and degeneration, further impairing vision and may even lead to permanent 
blindness. This is why as a person ages, their vision becomes progressively worse. 
 A protective measure against ROS is the use of antioxidant treatments. 
Antioxidants can be used to slow the rate of retinal degradation by counteracting damage 
from the reactive oxidative species. The body produces some antioxidants endogenously, 
but they can also be obtained outside of the body. They can be found in a variety of 
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antioxidant-rich foods, such as fruits, leafy green vegetables, and grains, and can also be 
obtained through dietary supplements. These include carotenoids like beta-carotene, 
lycopene, and vitamins A, C, and E (NCI, 2014). There are a variety of substances that 
act as antioxidants, like the ones mentioned before, in addition to glutathione, coenzyme 
Q10, lipoic acid, flavonoids, phenols, polyphenols, phytoestrogens, etc., all having 
different properties and roles against ROS (Harvard, 2017). In the case of preventing 
retinal degradation to improve outcomes in terms of vision integrity and function, 
antioxidants can be employed to protect against the damage from reactive oxidative 
species. However, because of physiological barriers, antioxidants cannot simply be taken 
orally and expected to be able to reach its target, i.e. the retina, to enact its protection. 
 This is due to the way that the eye is structured. The retina is located in the 
posterior chamber of the eye, which is generally challenging to access (Kaufman, 2011). 
There is a blood-retinal barrier, which is formed by retinal capillaries and tight junctions 
of retinal vascular endothelium that limit drug access from the general circulation. If 
taken orally, antioxidants would face a number of problems in trying to reach the retina. 
Firstly, it would undergo first-pass metabolism to which oral drugs are susceptible. This 
limits the amount of drug available to be absorbed and to be effective in the body. 
Secondly, dietary antioxidants, such as flavonoids, tend to be poorly soluble. Low 
solubility negatively affects dissolution rates, which limits how much of the drug can be 
absorbed into the circulatory system. This, in turn, limits the bioavailability of the drug 
for use in the body. Lastly, even if the drug were able to be absorbed into the circulatory 
system, not only would it be severely limited in terms of bioavailability, but also it would 
not be able to effectively reach its target due to the blood-retina barrier and lack of 
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circulation in the back of the eye. Thus, taking antioxidants as an oral dosage form would 
not be a viable option when targeting the retina. 
 Drug administration directly to the eye would be a more effective route 
compared to oral dosing. There are several ocular dosage forms and drug delivery 
systems, though these too are not without their challenges (see Figure 3 and Table 2). 
Some routes of administration include topical and injectable. Drugs administered through 
the topical route are most commonly in the form of eye drops, are noninvasive, and have 
high patient compliance. These are generally better for delivery to the anterior part of the 
eye. This is because there are several barriers that prevent absorption towards the back of 
the eye. Firstly, blinking and the production of tears can quickly wash away the drug and 
clear it from the eye. In fact, the majority of topically administered dosages are washed 
away within 15-30 seconds after instillation (Gaudana, 2010). Thus, very little of the drug 
is in contact with the eye long enough to be absorbed, accounting for less than 5% of the 
applied dose. Secondly, even if the drug were absorbed from the surface of the eye, it 
would have to pass through all layers of cornea, including the epithelium, stroma, and 
endothelium, to reach the aqueous humor, the fluid that fills the anterior part of the eye. 
Each layer has alternating hydrophilicity and lipophilicity that the drug must be 
compatible with in order to pass through the layers. The epithelium is lipophilic and so 
resists the permeation of hydrophilic drugs. The stroma is hydrophilic and resists the 
permeation of lipophilic drugs. The endothelium is similar to the epithelium in that it is 
lipophilic and resists hydrophilic drugs (Kaufman, 2011). In order to permeate through 
the corneal layers, the drug must be amphipathic, meaning it must possess both lipophilic 
and hydrophilic characteristics to pass through the respective layers. A way to bypass this 
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requirement would be to deliver the drug via injection, specifically intravitreal injections. 
Injections bypass the mechanical barriers, i.e. the different layers of the eye, to deliver the 
drug directly to the posterior segment of the eye into the vitreous humor (Gaudana, 
2010). It is a more effective route compared to topical administration in terms of drug 
delivery to the back of the eye, but it is not very patient compliant as it is very invasive. 
Additionally, because drug distribution in the vitreous humor is not uniform due to lack 
of circulation, only small molecules can rapidly distribute through the vitreous humor as 
distribution of larger molecules is limited. 
 
Figure 3. Routes of Administration for Ocular Drug Delivery 
Source: Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular Drug Delivery.  
The AAPS Journal. 2010;12(3):348-360. 
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 Many studies over the past few years have demonstrated the effectiveness 
of nanotechnology in ocular drug delivery. In one study, the administration of very small 
sized molecules (20 nm) of gold resulted in the particles readily passing through the 
blood-retinal barrier, which, as stated before, is a major barrier in getting the drug to the 
retina, and distributing in all the retinal layers without cytotoxicity (Gaudana, 2010). 
Increased penetrance and better distribution of small molecules, specifically 
nanoparticles, in the posterior segment of the eye would increase bioavailability and 
consequently pharmacological activity, which in turn can improve health outcomes. In 
this research, two nanoparticle formulations, solid lipid nanoparticles and nanostructured 
lipid carriers, were being investigated for efficacy in delivering quercetin, an antioxidant 
flavonoid, into the eye for retinal neuroprotection, compared against hot melt cast films. 
Many studies have been performed with quercetin nanoparticles targeted at various areas 
of the body and through different dosage routes, but to our knowledge, there are no 
known studies aimed for delivery into the eye. The advantages of using a topical 
administration route are high patient compliance and ease of modification to improve 
drug solubility, and these paired with the advantages of nanoparticle formulations makes 
them promising candidates for ocular drug delivery. 
1.1 Solid Lipid Nanoparticles: 
 Solid lipid nanoparticles, or SLNs, are dispersions that contain particles 
that have an average size of 500 nanometers or smaller and that contain low microparticle 
content (Mehnert, 2012). These nanoparticle dispersions are commonly and effectively 
produced via a high pressure homogenization process. As the name suggests, solid lipid 
9 
nanoparticle formulations use solid lipids, such as trilaurin, tripalmitin, glyceryl 
monostearate, glyceryl behenate, and stearic acid, for the lipid phase instead of lipid oils, 
primarily as a means to control drug release and to increase stability in vivo. Drugs 
encapsulated in a solid lipid have considerably lower mobility, and thus slower drug 
release from the lipids, compared to drugs encapsulated in liquid oil. The solid lipids also 
remain in a solid form at body temperature, which contributes to higher stability of the 
delivery system in vivo (Beloqui, 2016). In addition to controlled drug release, SLNs 
have many other advantages as a drug delivery system. These advantages include 
increased drug stability, high drug payload, ability to incorporate lipophilic and 
hydrophilic drugs, no biotoxicity or use of organic solvents, and ease in large scale 
production and sterilization (Mehnert, 2012). 
 The general formulation of SLNs includes a lipid phase containing the 
solid lipid and drug, an aqueous phase, and emulsifiers to stabilize the lipid dispersion 
and to prevent particle agglomeration. Formulations can also include cyclodextrins, 
which are cyclic oligosaccharides with hydrophobic inner cores and hydrophilic outer 
surfaces. Many studies have been performed to demonstrate that the addition of 
cyclodextrins is beneficial in the formulation process (Adelli “Effect”, 2015; Srirangam, 
2012). The use of cyclodextrins in the SLN formulations not only enhances the solubility 
of lipophilic drugs by forming soluble complexes with the drugs (i.e., encapsulating the 
drug in the core), but it also improves drug permeability across biological membranes by 
increasing the availability of drug molecules at the surface of the membranes (Adelli 
“Effect”, 2015). These advantages, in turn, increase the bioavailability and consequently, 
the action of the drug at the target site. 
10 
 There are many different methods and techniques that can be used to 
produce SLN formulations (Mehnert, 2012). Some examples include high shear 
homogenization and ultrasound, high pressure homogenization, solvent emulsification 
and evaporation, and microemulsion dilutions. Under the high pressure homogenization 
method, there are two different techniques: hot homogenization and cold 
homogenization. A schematic of these two techniques is shown below in Figure 4. In this 
research study, the hot high pressure homogenization technique was used, which 
produces a nanoemulsion that sports the advantages of highly impeded lipid 
crystallization and prolonged storage as a supercooled melt.  
 
Figure 4. Hot vs. Cold Homogenization Techniques 
Source: Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and 
applications. Advanced Drug Delivery Reviews 2012; 64:83-101. 
11 
 In characterizing SLN formulations, the goal parameters are small and 
uniform particle sizes (less than 500 nm), low polydispersity index, and high magnitude 
of zeta potential. These specific parameters would ensure the most stable and 
homogeneously distributed formulation. Studies suggest that smaller (nanoparticle) sizes 
have slightly faster release rates when compared to larger (microparticle) sizes (Dan, 
2016). Polydispersity index measures the degree of non-uniformity, or rather, the 
deviation from uniformity in a dispersion. A low value for PDI would indicate a more 
evenly distributed formulation with uniform particle sizes. Zeta potential measures the 
magnitude of electric repulsion between particles. A high magnitude for zeta potential 
would mean that there is strong electric repulsion between the particles, which would 
decrease the likelihood of particle aggregation in the dispersion, and thus, would increase 
the stability of the formulation. 
 1.2 Nanostructured Lipid Carriers: 
 Nanostructured lipid carriers, or NLCs, constitute another drug delivery 
system with controlled drug release from nanoparticles. Not only have NLCs been shown 
to improve drug permeation and aqueous solubility of drugs, but also these formulations 
have demonstrated to increase drug retention and more importantly, to enhance the 
antioxidant and anti-inflammatory effects of quercetin (Beloqui, 2016). The 
differentiating characteristic of NLCs from SLNs is the incorporation of a liquid lipid, 
such as caprylic or capric triglycerides, lauroyl polyoxyglycerides, monoacylglycerols, 
and soy lecithin, in the solid lipid matrix, which results in an unstructured solid lipid 
matrix. The use of a liquid lipid in the lipid matrix increases the amount of openings and 
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gaps in the solid matrix, allowing for more of the drug to be encapsulated into the 
nanoparticles as well as increasing the drug release rate by increasing the surface 
permeability of the nanoparticles. Comparatively, drug release through the solid lipid is 
slower and more limited than the drug release through the liquid lipid due to the lower 
solubility of the drug in the solid lipid (Dan, 2016). The incorporation of the liquid lipid 
improves drug solubility in the nanoparticles and increases the rate and amount of drug 
release while still controlling how much is released into the body at a time. The lipid 
blends can be mixed in any ratio from 70:30 up to 99.9:0.1, solid lipid to liquid lipid 
(Beloqui, 2016). Otherwise, the general formulation is the same as that of SLNs. The 
NLC formulation consists of a lipid phase which contains the drug, an aqueous phase, 
and surfactants accounting for about 1.5-5% w/v of the formulation. 
 NLCs can be made using a variety of methods, such as micro-
emulsification and solvent displacement, but similar to SLNs, the most preferred method 
is high pressure homogenization, specifically hot homogenization, as it does not require 
the use of solvents during the preparation process and can be easily implemented in large 
scale production. Due to the presence of water in these formulations, physical instability 
caused by microbial growth is a major concern. To circumvent this problem and to 
preserve ideal nanoparticle characteristics, the formulation can either be lyophilized to 
remove water content and form a solid formulation, or a preservative can be added to the 
formulation to inhibit microbial growth while maintaining a liquid formulation. Criteria 
for a lyophilized formulation include short reconstitution time, easy resuspension in 
water, no changes to particle size distribution of nanoparticles, and preserved drug 
activity. To prevent aggregation of the lyophilized particles, a cryoprotectant is required. 
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One such cryoprotectant shown in studies to effectively prevent particle aggregation 
while preserving the stability of the nanoparticle shell structure is trehalose. However, 
caution should be taken when using a lyophilization method as the use of cyroprotectants 
often implies alteration of initial nanoparticle surface properties. Other preservation 
methods may be more favored and advised in this case, such as the use of a preservative 
while maintaining the water content of the formulation. This method ensures that there 
are minimal changes to the nanoparticle surface properties (e.g., zeta potential). The ideal 
preservative should be highly hydrophilic, non-ionic, and have little affinity to the 
particle surface. 
 The goal parameters of NLCs are also the same as those for SLNs. The 
desired formulation should have small (less than 500 nanometers) and uniform particle 
sizes, low polydispersity index, and high magnitude of zeta potential to ensure the 
greatest stability and homogeneous distribution. 
1.3 Hot Melt Cast Films: 
 Hot melt cast films are yet another drug delivery system that is used for 
improving bioavailability of poorly soluble drugs. They are solid molecular dispersions 
of a drug or active pharmaceutical ingredient in a polymeric matrix that provide 
controlled and sustained drug release while eliminating the use of solvents in the 
preparation process (Repka, 2007). These formulations have the advantages of being 
quicker and more efficient to produce as well as increased efficiency of drug delivery. 
14 
 The general formulation for hot melt films includes a blend of the active 
ingredient or drug, a thermoplastic polymeric carrier, and other processing aids like 
plasticizers or antioxidants. This blend is then heated and softened before being pressed 
in a die to form the film. This method is known as hot melt extrusion, or HME, when an 
extruder is used, and it can be used to form a variety of other dosage forms as well, such 
as granules, pellets, tablets, capsules, and implants. There are specific criteria for 
materials used in the HME process, a major one being thermal stability as the materials 
must be able to withstand the high temperatures at which the process is performed 
without degrading (Crowley, 2007). They must also be able to easily deform while in the 
extruder and solidify upon exiting the extruder to form a solid dosage form. 
 In regards to the active pharmaceutical ingredients, the drug contained in 
the dosage form may be dispersed in the polymeric matrix as undissolved particles, a 
solid solution, or some combination of both. Because of this, the dosage form may be a 
solid dispersion system, in which the drug is undissolved and dispersed in the carrier 
matrix, or a solid solution system, in which the drug is dissolved in the carrier matrix. 
Solid dispersions have the advantages of being more stable and more easily produced 
compared to solid solutions. However, solid solutions have the advantage of exhibiting 
potentially higher bioavailability of poorly soluble drugs over solid dispersions. The 
properties of the drug can also affect the functionality of other materials used in the 
formulation. The drug can negatively affect the formulation by decreasing the viscosity 
or inhibiting the hardening of the matrix, which results in a dosage form that will be 
poorly handled and unusable. On the other hand, the drug could positively affect the 
formulation by lowering the glass transition temperature of the polymeric carrier, which 
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can improve processing conditions. Thus, the drug should be compatible with the other 
ingredients used in the formulation in order to yield a good dosage form. 
 A second major component of the formulation is the carrier, which is 
generally a polymer, a low melting point wax, or a mixture of low melting point 
substances in which the drug or active pharmaceutical ingredient is embedded. The 
compatibility of the drug and carrier compounds should be taken into account as there is 
the possibility of the formation of a eutectic mixture when mixing a low melting drug 
with a low melting carrier, which would result in a dosage form that would not be able to 
solidify. The physical and chemical properties of the carriers can also highly affect the 
drug release from the dosage form. Drug release mechanisms differ depending on the 
type of carrier used. Water insoluble carriers exhibit a diffusion controlled drug release 
rate while water soluble carriers exhibit a diffusion and erosion drug release mechanism. 
Ionic or pH dependent carriers can be used to achieve zero-order or site-specific drug 
release. Functional excipients can be added to the carrier to modulate the rate of drug 
release as well, by altering either the porosity, tortuosity, viscosity, or rate of 
disintegration of the polymeric matrix and the resulting dosage form. 
 Plasticizers are the third important component of the formulation. 
Plasticizers are low molecular weight compounds that can have two roles in the 
formulation process: increase polymeric flexibility and decrease processing temperatures. 
They can be used to soften the polymers to make the resulting dosage form more flexible. 
They can also improve processing conditions by decreasing the glass transition 
temperature and melt viscosity of a polymer by increasing the free volume between 
polymer chains while decreasing the ease of their movement with respect to each other, 
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which allows the HME process to be conducted at lower temperatures and with less 
energy. This improves the drug and carrier stability by reducing their degradation. 
Plasticizers used in the formulation should have good efficiency, stability, polymer-
plasticizer compatibility, and permanence, as these can affect the physical and 
mechanical properties as well as the drug release rate of the dosage form. 
 Lastly, there are other processing aids, like antioxidants, acid receptors, 
and light absorbers, which can be used to improve the stability of the other components 
and the overall formulation. Antioxidants, which can be either preventive or chain-
breaking, are used to protect the compounds against free radicals and oxidative 
degradation. Preventive antioxidants prevent the initiation of free radical chain reactions 
while chain breaking antioxidants inhibit free radical chain reactions. Preventive 
antioxidants include reducing agents, which preferentially undergo oxidation and thus 
protect the other compounds from oxidative damage, and chelating agents, which form 
stable complexes with the metal ions to prevent them from catalyzing the formation of 
free radicals and thus decrease the number of free radicals produced. Chain breaking 
antioxidants include hindered phenols and aromatic amines, which have very weak O-H 
and N-H bonds, respectively, that will undergo a higher rate of oxidation and thus reduce 
oxidation of the other formulation components. Other processing aids can be used to 
improve processing conditions, such as glyceryl monostearate, which can act as a thermal 
lubricant, and Vitamin E TPGS, which can enhance drug absorption. 
 The main goal parameters for hot melt cast films are homogenous 
distribution of the drug in the polymeric matrix, high stability of the drug, polymer, and 
any additives, and good rate and quantity of drug release. 
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1.4 Quercetin: 
 Quercetin, which has the chemical name of 2-(3,4-Dihydroxyphenyl)-
3,5,7-trihydroxy-4H-1-benzopyran-4-one, is a bioflavonoid aglycone, specifically of the 
flavonol subclass, meaning that it has a 3-hydroxyflavone backbone and lacks attached 
sugars, as shown in Figure 5 (Kelly, 2011).  
 
Figure 5. Quercetin Structure 
Source: Quercetin [product insert]. Ann Arbor, MI: Cayman 
Chemical Company; 2016. 
 
It is a crystalline solid that has a bright citron yellow color. It is lipophilic and 
hydrophobic in nature so its solubility in water is poor to nonexistent (poor in hot water 
and entirely insoluble in cold water). A way to improve its solubility in water is to 
convert it to a glycoside. This can be done by replacing one of the hydroxyl groups, 
commonly the one at position 3, with a glycosyl group, which can be any sugar such as 
glucose, rhamnose, or rutinose (see Figure 6). A glycoside group at position 3 is known 
as isoquercitin. The addition of a glycosyl group changes the chemical properties of the 
drug, including solubility, absorption, and in vivo effects. Specifically, the addition of the 
glycosyl group increases the water solubility of quercetin. 
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Figure 6. Quercetin-3-O-β-Glucoside Structure 
Source: Bentz AB. Review of quercetin: chemistry, antioxidant properties, and 
bioavailability. Journal of Young Investigators 2009. 
 
Otherwise, if quercetin were to be solubilized in an aqueous buffer, it would first need to 
be dissolved in DMSO and then diluted with the aqueous buffer. Quercetin is rather well 
soluble in organic solvents, such as ethanol, acetic acid, dimethyl formamide, and 
dimethyl sulfoxide. In ethanol, quercetin has a solubility of 2 mg/mL whereas in DMF 
and DMSO, it has a solubility of 30 mg/mL (up to 100 mM) [Cayman, 2016; Abcam, 
2017]. 
 Quercetin is found in a variety of foods, such as onions, shallots, apples, 
berries, grapes, and tea leaves, as well as in some medicinal botanicals, such as Ginkgo 
biloba, Hypericum perforatum (St. John’s wort), and Sambucus canadensis (elder) 
[Kelly, 2011]. It is commercially available as dietary supplements and as additives to 
foods and beverages. It has many potential uses, as demonstrated in several test tube 
studies, though more research is required in humans to prove efficacy. Quercetin has 
been demonstrated to prevent immune cells from releasing histamine, which is 
responsible for allergic reactions, as well as to prevent free radicals from activating 
transcription factors that generate pro-inflammatory cytokines, making it a good 
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candidate for reducing symptoms of allergies and inflammatory conditions (Erhlich, 
2015; Bentz, 2009). In respect to heart disease and hypertension, various studies, 
including test tube, animal, and population-based studies, suggest that the flavonoids 
found in red wine like quercetin may reduce blood pressure and the risk of 
atherosclerosis. It can also help in hypercholesterolemia by reducing LDL levels. It does 
so by exhibiting a potent inhibitory effect on lipid absorption in the gastrointestinal tract, 
and it also helps eliminate lipids from the body by enhancing lipid metabolism in the 
liver, which ultimately protects the body against damage by LDL cholesterol 
(Flavonoids, 2017). Quercetin has also been shown to exhibit antitumor characteristics in 
terms of inhibiting the growth of cancer cells and tumors. In one study, it was suggested 
to be more efficacious in tumor growth inhibition than resveratrol (Erhlich, 2015). These 
are only a few of the numerous clinical indications in which quercetin may have 
beneficial effects. 
 In respect to this research, the most important characteristic of quercetin, 
however, is its antioxidant properties. Quercetin is a strong antioxidant that can bind 
transition metal ions, scavenge free radicals, and increase glutathione levels (Bentz, 
2009). Specifically it can inhibit lipid peroxidation, which is the process by which 
unsaturated fatty acids are converted to free radicals by hydrogen extraction. When the 
free radicals are oxidized by molecular oxygen, lipid peroxy radicals are created, which 
then extract hydrogen molecules from other unsaturated fatty acids and produce more 
free radicals in an amplifying cascade process. Trace amounts of transition metal ions can 
catalyze this process. The overproduction of free radicals over a prolonged period of time 
can lead to extensive damage to various body tissues, including those of the heart, brain, 
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eye, and associated structures. Quercetin not only hinders the production of free radicals 
significantly by mopping up any transition metal ions, but also it greatly reduces the 
number of free radicals already made in the body by scavenging and neutralizing them. 
Additionally, it can increase glutathione levels in the brain to protect neurons from 
oxidative damage by competitively converting hydrogen peroxide to oxygen and water, 
instead of allowing superoxide dismutase to convert it to a superoxide radical. This 
allows it to reduce oxidative stress in the body, protecting it from a myriad of ailments, 
such as cardiovascular disorders, neurodegenerative diseases, atherosclerosis, chronic 
inflammation, and retinal degeneration. 
 In terms of safety and toxicity, quercetin has been demonstrated to be well 
tolerated in human studies. Doses as high as 1,000 mg/day were administered for several 
months, and no adverse effects on liver and kidney functions, hematology, or serum 
electrolytes were produced as a result (Kelly, 2011). However, one potentially significant 
concern with respect to toxicity is the concomitant use of digoxin with high doses of 
quercetin, which has been shown to have a lethal effect in one pig study. More research is 
needed to determine safe dosage levels of quercetin when used concomitantly, but for the 
purpose of our research, the dose of quercetin used was deemed to be safe for human use. 
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2. MATERIALS AND METHODS: 
2.1 Materials: 
 Quercetin was purchased from Tocris Bioscience. Glycerol monostearate 
and Compritol ATO 888® were graciously donated by Gattefossé. Miglyol 812® was 
purchased from Condea. Tween 80 and methyl-beta-cyclodextrin were purchased from 
Acros Organic. Poloxamer 188 was purchased from Spectrum. Glycerin was purchased 
from PCCA. Acetonitrile and dimethyl sulfoxide were purchased from Fisher Chemical. 
Whole rabbit eye globes were purchased from Pel-Freez Biologics. The rabbit eye globes 
were dissected in lab to collect the corneas for use in the permeability studies. 
2.2 Methods: 
Solid Lipid Nanoparticles: 
 Quercetin solid lipid nanoparticles, or SLNs, were prepared by probe 
sonication method. The lipid phase was prepared with a solid lipid (0.7% w/v Glycerol 
monostearate) in combination with 1.3% w/v Compritol ATO 888® and heated on a hot 
plate at 80
o
C. Quercetin was dissolved in 100 µL of dimethyl sulfoxide and added to 
2.25% w/v glycerin. This mixture was added to the melted lipid phase. The aqueous 
phase was prepared using 0.75% w/v Tween 80®, Poloxomer 188®, and filtered water 
and heated on the hot plate at 80
o
C. The aqueous phase was then added to the lipid phase 
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while stirring at 600 rpm for 2 minutes. The final concentration of quercetin was 0.1% 
w/v. The premix was homogenized with an Ultra-Turrax® at 16,000 rpm for 3 minutes to 
form a coarse emulsion. This coarse emulsion was then subjected to probe sonication at a 
15-second pulse rate for 3 minutes. The final emulsion was allowed to cool to form the 
nanoparticles. 
Nanostructured Lipid Carriers: 
 Quercetin nanostructured lipid carriers, or NLCs, were also prepared by 
probe sonication method. The method is almost exactly the same as that for the SLN 
formulation, except that the lipid phase was prepared with a liquid lipid (0.7% w/v 
Miglyol 812®) in combination with 1.3% w/v Compritol ATO 888®, which was then 
heated on a hot plate at 80
o
C. Quercetin was dissolved in 100 µL of dimethyl sulfoxide 
and added to 2.25% w/v glycerin. This mixture was then added to the melted lipid phase. 
The aqueous phase was prepared using 0.75% w/v Tween 80®, Poloxomer 188®, and 
filtered water and heated on the hot plate at 80
o
C. The aqueous phase was added to the 
lipid phase while stirring at 600 rpm for 2 minutes. The final concentration of quercetin 
was 0.1% w/v. The premix was homogenized with an Ultra-Turrax® at 16,000 rpm for 3 
minutes to form a coarse emulsion, which was then subjected to probe sonication at a 15-
second pulse rate for 3 minutes. The final emulsion was allowed to cool to form the 
nanoparticles. 
Hot Melt Cast Films: 
 Quercetin films were prepared by melt-cast method. Polyethylene oxide 
N10 was used as the matrix forming polymer. Quercetin and PEO N10 were mixed via 
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geometric dilution to prepare the physical mixture. The drug load in the film was 10% 
w/w. A 10 mm die was placed over a brass plate and heated on a hot plate at 75°C for at 
least one minute. The physical mixture was poured into the center of the die and 
compressed for a few seconds to form a flat matrix surface. The film was heated on the 
hot plate for an additional minute so that the mixture was completely melted and then 
removed to cool. When completely cooled, the film was cut to collect samples that 
weighed approximately 8 mg each. 
Characterization of Nanoparticles: 
 Mobile phase of acetonitrile:water (ACN:H2O, 40:60) was prepared. 
Quercetin was dissolved in dimethyl sulfoxide (DMSO) to make a 1 mg/mL stock 
solution for the standards. Varying volumes of the stock solution were diluted with the 
mobile phase to make standards of the following concentrations: 1 μg, 2 μg, 5 μg, 10 μg, 
and 20 μg. The standards were analyzed using UV analysis at a wavelength of 369 nm to 
determine the light absorbance trend, or calibration curve, of quercetin to which the 
nanoparticle emulsions will be compared. 
 The SLN and NLC formulations were diluted 500 times with purified 
water and analyzed using a zetasizer (Malvern Instruments, Ltd.) to determine the size, 
polydispersity index, and zeta potential of the particles. The goal was to have small 
particle sizes, low polydispersity index, and high magnitude of zeta potential for the most 
stable and homogeneous formulation. 
 Entrapment efficiency, which is a measure of how much drug is entrapped 
in the nanoparticles, was performed by centrifuging 500 μL of each formulation with a 
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filter for 15 minutes. 100 μL of the centrifuged filtrate was drawn, diluted with 900 μL of 
the mobile phase, and then vortexed to ensure thorough and homogeneous mixing. 
 Assay was performed to determine quercetin content in the nanoparticles. 
For each formulation, 100 μL of formulation were added to 900 μL of a mixture of 
DMSO and methanol (50:50) and sonicated for 10 minutes. After sonication, the mixture 
was centrifuged for 15 minutes. From this, 100 μL of the supernatant was drawn and 
diluted with 900 μL of the mobile phase before being vortexed to ensure thorough and 
homogeneous mixing. 
 All samples collected from entrapment efficiency and assays were 
analyzed in triplicates using HPLC-UV method with a Kinetex® 5 μm EVO C18 100 Å 
LC column (250 x 4.6 mm). 
Characterization of Films: 
 Mobile phase of acetonitrile:water (ACN:H2O, 40:60) was prepared. 
Quercetin was dissolved in dimethyl sulfoxide (DMSO) to make a 1 mg/mL stock 
solution for the standards. Varying volumes of the stock solution were diluted with 
acetonitrile to make standards of the following concentrations: 1 μg, 2 μg, 5 μg, 10 μg, 
and 20 μg. The standards were analyzed using UV analysis at a wavelength of 369 nm to 
determine the calibration curve of quercetin to which the film samples will be compared. 
 Samples of approximately 8 mg were cut from quercetin films and added 
to 2 mL of acetonitrile. This mixture was then sonicated for 5 minutes until the film was 
completely dissolved. After sonication, the stock was diluted by a factor of 20. All 
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samples were collected and analyzed in triplicates using UV analysis at a wavelength of 
369 nm. 
Permeability Studies: 
 Release and permeability of quercetin from the nanoparticles were studied 
using a vertical dialysis cassette with a 10,000 Dalton MWCO membrane. Isotonic 
phosphate buffer saline, or IPBS, was made with 5% methyl-beta-cyclodextrin. IPBS 
served as the receiver medium. 18 mL of IPBS was filled into the vial, and 1 mL of 
formulation was filled into the cassette. Measurements were taken at 15, 30, 60, 90, 120, 
150, and 180 minute time points, at which time 1 mL of the receiver medium was drawn 
and 1 mL of IPBS was added into the vial. All samples collected were analyzed in 
triplicates under HPLC-UV method. 
 Permeability of quercetin from NLCs and films was studied using fresh 
rabbit cornea in a side-by-side diffusion apparatus, maintained at 34°C using a circulating 
water bath.  IPBS with 5% methyl-beta-cyclodextrin was made. Spectra/Por® membrane 
(10,000 Daltons MWCO) were cut and soaked in IPBS for 30 minutes. Side-by-side 
diffusion cells were set up so that the fresh rabbit cornea and Spectra/Por® membrane 
were sandwiched between the cells. For the film studies, the films were cut to 
approximately 45 mg and wetted with IPBS. They were then sandwiched between the 
rabbit cornea and Spectra/Por® membrane, in the following order: donor 
cellSpectra/Por® membranequercetin filmcornearecipient cell (see Figure 7). 
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Figure 7. Side-by-Side Diffusion Apparatus Setup 
Source: Adelli GR, Hingorani T, Punyamurthula N, et al. Evaluation of topical hesperetin 
matrix film for back-of-the-eye delivery. European Journal of Pharmaceutics and 
Biopharmaceutics 2015; 92:74-82. 
 
Both the donor and recipient cells for the film studies were filled with 3.2 mL of IPBS. 
For the NLC formulations and the control, which was 3 mg of pure quercetin mixed with 
IPBS, 3.2 mL of each formulation were added into their respective donor cells, and 3.2 
mL of IPBS were added to the recipient cells. Measurements were taken at 30, 60, 90, 
120, 150, and 180 minute time points. After flushing a few times to mix the receiver 
medium, 0.6 mL samples were drawn from the recipient cell, except for the films, for 
which samples were collected from both donor and recipient cells, and 0.6 mL of IPBS 
was added to the cells to replace the volume removed. The samples were analyzed in 
triplicates using UV analysis at a wavelength of 369 nm.
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3. RESULTS: 
3.1 Characterizations of Nanoparticles and Films: 
  The solid lipid nanoparticles demonstrated an average particle size of 65.4 
r.nm, polydispersity index of 0.29, and zeta potential of -12.3 mV. Assay and entrapment 
efficiency results were 78.4 ± 1.6% and 90.9 ± 0.3%, respectively. Drug release across 
the Spectra/Por® membrane was 33.3 ± 1.5%. These parameters are summarized below 
in Table 3. Particle size distribution is shown in Figure 8. 
Table 3. Physicochemical Characterization of SLN Formulations 
 
 
 
Figure 8. SLN Particle Size Distribution by Intensity 
Parameters Solid Lipid Nanoparticles 
Particle Size (r.nm) 65.4 
Polydispersity Index 0.29 
Zeta Potential (mV) -12.3 
Assay 78.4 ± 1.6 
Entrapment Efficiency 90.9 ± 0.3 
% Release across  
Spectra/Por® Membrane 
33.3 ± 1.5 
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 The nanostructured lipid carriers demonstrated an average particle size of 
46.1 r.nm, polydispersity index of 0.18, and zeta potential of -16.2 mV. Assay and 
entrapment efficiency results were 86.6 ± 0.2% and 93.4 ± 0.1%, respectively. Drug 
release across the Spectra/Por® membrane was 47.1 ± 7.9%. These parameters are 
summarized below in Table 4, and particle size distribution is shown below in Figure 9. 
The comparison of the particle size distributions for the SLN and NLC formulations is 
shown below in Figure 10.  
 
Table 4. Physicochemical Characterization of NLC Formulations 
 
 
  
Figure 9. NLC Particle Size Distribution by Intensity 
 
Parameters Nanostructured Lipid Carriers 
Particle Size (r.nm) 46.1 
Polydispersity Index 0.18 
Zeta Potential (mV) -16.2 
Assay 86.6 ± 0.2 
Entrapment Efficiency 93.4 ± 0.1 
% Release across  
Spectra/Por® Membrane 
47.1 ± 7.9 
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Figure 10. SLN vs. NLC Size Distributions by Intensity 
  Hot melt cast films demonstrated assay results of 76.3 ± 4.1%. Particle 
size, polydispersity index, zeta potential, and entrapment efficiency are parameters 
designed more for nanoparticle systems and were not evaluated with the hot melt cast 
films. Drug release across Spectra/Por® membranes was also not evaluated with the 
films. 
3.2 Corneal Permeability Studies: 
 All samples were analyzed via UV analysis at a wavelength of 369 nm, at 
which the standard calibration curve had an R
2
 value of 0.9989. TGA data indicated that 
physical mixtures were stable under the utilized processing temperature. Permeability 
across the rabbit cornea for quercetin films, NLCs, and control are shown in Figures 11, 
12, and 13, respectively. 
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Figure 11. Permeability of Quercetin Films 
 
 
Figure 12. Permeability of Quercetin NLCs 
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Figure 13. Permeability of Quercetin Control 
 The results from the permeability studies, in terms of rate, flux, and 
permeability, are summarized in Table 5 and Figure 14. Transcorneal flux, which is the 
amount of drug that crosses the cornea per minute per area squared (in this case, the area 
of the cornea is 0.636 cm), of quercetin control, NLCs, and films were 0.026 ± 0.002, 
0.036 ± 0.006, and 0.144 ± 0.009, respectively. Permeability was calculated as flux 
normalized by assay. 
 
Table 5. Results for Permeability Studies (Rate, Flux, Permeability) 
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Rate (µg/min) Flux (µg/min/cm
2
) 
Permeability X 10
6
 
(cm/sec) 
Control 0.0165 ± 0.002 0.0260 ± 0.002 0.135 ± 0.012 
NLCs 0.0227 ± 0.004 0.0357 ± 0.006 0.186 ± 0.030 
Films 0.1435 ± 0.006 0.1435 ± 0.009 0.747 ± 0.047 
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Figure 14. Transcorneal Permeability of Quercetin in Different Formulations 
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4. DISCUSSION: 
 The goal parameters for the nanoparticle formulations were to have small 
particle sizes, low polydispersity index, and high magnitude of zeta potential. Both the 
solid lipid nanoparticles and the nanostructured lipid carriers successfully met and fit well 
within these goal parameters. Particle sizes for both formulations were well below 500 
nm. The peak of the particle size distribution for the NLC formulation was higher and 
narrower compared to the peak for the SLN formulation, as the intensity was noticeably 
greater and the particle sizes were less variable. Polydispersity indices for both were 
close to zero (0), which is the most ideal polydispersity index in order to have a 
completely uniform formulation. Zeta potentials for both were relatively high in 
magnitude as well (between -10 and -20 mV). Both entrapment efficiencies were at least 
90% or higher. Drug releases across the Spectra/Por® membrane for both formulations, 
on the other hand, were relatively low (around 30-50%). When comparing assays for all 
three formulations (SLNs, NLCs, and films), film assay results were the lowest (by 2%), 
and NLCs were the highest (by about 8%), with SLNs in between the two. 
 In all regards, the NLC formulation had better physicochemical 
characteristics compared to the SLN formulation. This is due to the nature of the lipid 
matrix shells of the nanoparticles. Because solid lipid nanoparticle formulations use only 
solid lipids, the matrix shells are completely solid and continuous, which has limited 
permeability. Not only does this affect how much drug can be encapsulated in the 
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nanoparticles, but it also affects how the drug diffuses out of the nanoparticles. 
Specifically, this structure results in a relatively low drug load, limited drug release, and 
drug expulsion during storage. With nanostructured lipid carriers, on the other hand, the 
incorporation of a liquid lipid to the solid lipid matrix results in a disrupted and highly 
permeable nanoparticle shell. This structure allows for a higher drug load, greater drug 
release, and long term drug stability. Thus, from these differences (summarized in Figure 
15), we would expect to see that the NLC formulation would show better characteristics 
than the SLN formulation, which it did. 
 
 
Figure 15. Advantages of NLC Structure over SLN Structure 
Source: Beloqui A, Solinis MA, Rodríguez-Gascón A, Almeida AJ, Préat V. 
Nanostructured lipid carriers: promising drug delivery systems for future clinics.  
Nanomedicine: Nanotechnology, Biology and Medicine 2016; 12:143-161. 
 
35 
 To compare how well quercetin permeates from the hot melt cast film 
across corneas as opposed to permeation from the nanoparticles, we used a control of 
pure quercetin in addition to the NLC formulation, which was chosen because it 
demonstrated better parameters and physicochemical characteristics compared to the 
SLNs. The three main parameters tested in the permeability studies were rate, flux, and 
permeability. Rate was determined by how much drug, in micrograms (μg), crossed the 
cornea from the donor to the receiver cells, per minute, with concentrations extrapolated 
from the calibration curve based on the absorbance of the samples. The rate of drug 
release permeation for the control was the slowest, and the rate for the films was the 
highest by a significant margin (7-14x higher), with the rate of the NLCs in between the 
two. Flux was calculated as the amount of drug in micrograms that crosses the cornea per 
minute per area squared (area = 0.636 cm). Again, the flux for the control was the lowest, 
and the flux for the films was the highest by a good margin (4-5x higher). Flux for NLCs 
was in between the other two flux values. Lastly, permeability was calculated as flux 
normalized by assay and reported as centimeters per second. These results showed the 
same trends as with the other two parameters. The permeability of the control across the 
cornea was the lowest, the permeability of the drug from the NLCs was second highest, 
and the permeability of the drug from the films was the highest, once again by a good 
margin (4-6x higher). 
 In total, both formulations (NLCs and films) were more successful 
compared to the control in drug permeability across the cornea. However, the hot melt 
cast film formulation showed significantly better parameters in all respects compared to 
both the control and the NLC formulation.  
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5. CONCLUSION: 
 Vision problems have become an issue that progressively affects more and 
more people each year. With age and prolonged exposure to excessive amounts of 
reactive oxidative species comes increased potential for retinal degeneration, and 
consequently, vision impairment and/or loss. To protect against this, antioxidants can be 
used to neutralize the reactive oxidative species and inhibit excess production by not only 
scavenging ROS, but also by mopping up the metal ions that catalyze their production, 
thereby limiting the amount of ROS in the body. One such antioxidant is quercetin, a 
bioflavonoid that is found commonly in many foods and that exhibits strong antioxidant 
properties, among many other potential clinically beneficial uses. 
 Ocular drug delivery to the back of the eye is difficult, and many barriers 
must be overcome for successful drug delivery. Specialized drug delivery systems must 
be employed in such cases. Among these are nanoparticle emulsions, such as solid lipid 
nanoparticles and nanostructured lipid carriers, as well as hot melt cast films. These 
delivery systems have been demonstrated in many studies to be successful in delivering 
drugs to the eye, and they have the added benefit of high patient compliance, compared to 
other systems, such as intravitreal injections, which are successful but have less patient 
compliance. 
 Solid lipid nanoparticles, nanostructured lipid carriers, and hot melt cast 
films were employed in this study in hopes to be able to successfully deliver quercetin to 
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the back of the eye where it can act on the retina and protect it from degeneration by 
damage from reactive oxidative species. Upon optimization and characterization, 
quercetin nanoparticles were successfully prepared with a good particle size distribution 
and other physicochemical parameters. Further, in-vitro release and permeability values 
demonstrate that nanoparticles can be successfully employed for delivery of quercetin 
into the eye through the topical route of administration. The hot melt cast films were also 
demonstrated to have good release and permeability profiles. In fact, there was a 
significant enhancement of transcorneal permeability of quercetin films compared to the 
control and nanoparticles. These results demonstrate that hot melt cast films can also be 
successfully employed for delivery of quercetin into the eye through the topical route of 
administration and may be a better delivery system for quercetin administration 
compared to the nanoparticles. 
 Future direction for this research includes in-vivo testing of these drug 
delivery systems. Specifically, drug delivery in live animals can be performed to test 
permeability and absorption across corneas under physiologic conditions. A long term 
study can also be performed to test the extent of retinal neuroprotection that quercetin 
may have in protecting against damage from reactive oxidative species and consequent 
vision impairment. 
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